A Phase Ib Multicenter Dose-Finding And Safety Study Of GDC-0199 And Obinutuzumab in Patients With Relapsed Or Refractory Or Previously Untreated Chronic Lymphocytic Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose
approximately 30 months
No
Clinical Trials
Study Director
Genentech
United States: Food and Drug Administration
GP28331
NCT01685892
November 2012
August 2015
Name | Location |
---|---|
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Cleveland, Ohio 44195 | |
Nashville, Tennessee 37203-1632 | |
Eugene, Oregon | |
Charleston, West Virginia 25304 |